

# The Changing Landscape of Treatment in Developmental and Epileptic Encephalopathies

Elaine Wirrell MD

Mayo Clinic  
USA

# Disclosures

- DSMB member: Neurocrine, Encoded, GRIN Pharma, Acadia
- Consulting fees: Biocodex

# Learning Objectives

- What is meant by developmental and epileptic encephalopathy?
- How do we classify DEEs?
- How can optimize management of persons with DEE?

# Key Messages

- Development and Epileptic Encephalopathies are a group of severe epilepsies that onset in early life and are associated with:
  - Seizures that are typically frequent and drug-resistant
  - Intellectual disability and other comorbidities
- Both ***etiology*** and ***syndrome*** inform optimal management
- Optimal care must address both seizures as well comorbidities and support of families

# Key References

- *Zuberi et al.* ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions. *Epilepsia* 2022;63:1349-97.
- *Specchio et al.* International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions. *Epilepsia* 2022;63:1398-1442.
- *Scheffer et al.* Developmental and epileptic encephalopathies. *Nat Rev Dis Primers* 2024;10:61